Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo DrugZacks Investment Research • 01/12/26
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-TermZacks Investment Research • 01/12/26
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through InnovationGlobeNewsWire • 01/11/26
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for VitiligoGlobeNewsWire • 01/11/26
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair StoryThe Motley Fool • 12/27/25
S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to PositiveGlobeNewsWire • 12/24/25
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026The Motley Fool • 12/24/25
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®GlobeNewsWire • 12/19/25
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?The Motley Fool • 12/14/25
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks24/7 Wall Street • 12/11/25
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to PlayZacks Investment Research • 12/09/25
Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC FilingThe Motley Fool • 12/09/25
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in AdultsGlobeNewsWire • 12/09/25